The present disclosure generally relates to nanoparticles comprising an antibody, such as an anti-PD-1 antibody. Other aspects include methods of making and using such nanoparticles. In an embodiment, the nanoparticles comprise a diblock poly(lactic) acid-poly(ethylene)glycol (PLA-PEG) copolymer, a chemotherapeutic agent, and a prostate-specific membrane antigen (PSMA) targeting ligand.